V710, an experimental vaccine developed by Intercell and Merck, seems to show some promise in fighting infection caused by Staphylococcus aureus bacteria in patients with end-stage renal disease, according to a Bloomberg Business news report.
For their study, researchers assessed the impact of V710 on more than 200 individuals. The test subjects received a 60-μg dose or 90-μg dose of V710 or a placebo. The subjects received either one or two doses 28 days apart before receiving a single dose after 180 days.
All test subjects who received two V710 doses had dramatic increases of an antibody produced by the immune system to fight bacterial infection. Results from the study also showed no serious adverse outcomes. The Phase II study is part of a human-testing period. Regulatory bodies typically require three phases of human testing in order to obtain clearance, according to the news report.
Read the news report about V710.
Related Articles on Infection:
Infection Rates Decrease 6% in PA Hospitals
Improving Gloving Not Enough to Maintain Adequate Hand Hygiene
Data on Hospital-Acquired Conditions Reveal Faults at Wisconsin Hospitals
For their study, researchers assessed the impact of V710 on more than 200 individuals. The test subjects received a 60-μg dose or 90-μg dose of V710 or a placebo. The subjects received either one or two doses 28 days apart before receiving a single dose after 180 days.
All test subjects who received two V710 doses had dramatic increases of an antibody produced by the immune system to fight bacterial infection. Results from the study also showed no serious adverse outcomes. The Phase II study is part of a human-testing period. Regulatory bodies typically require three phases of human testing in order to obtain clearance, according to the news report.
Read the news report about V710.
Related Articles on Infection:
Infection Rates Decrease 6% in PA Hospitals
Improving Gloving Not Enough to Maintain Adequate Hand Hygiene
Data on Hospital-Acquired Conditions Reveal Faults at Wisconsin Hospitals